COUNTERPOINT: Should Lung Cancer Screening by Chest CT Scan Be a Covered Benefit? No

Chest

Volumn 147, Issue 2, 2015, Pages 289-292

  Courtright, Katherine ^a,b   Manaker, Scott ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BREAST CANCER; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; EDITORIAL; FALSE POSITIVE RESULT; HEALTH CARE COST; HUMAN; LUNG CANCER; MEDICARE; MORTALITY RATE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION EXPOSURE; RADIATION INDUCED NEOPLASM; SENSITIVITY AND SPECIFICITY; SMOKING; SURGICAL MORTALITY; THORAX RADIOGRAPHY; INSURANCE; LUNG TUMOR; RADIOGRAPHY;

HUMANS; INSURANCE COVERAGE; LUNG NEOPLASMS; MEDICARE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84928059937     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2815     Document Type: Editorial

References (22)

1. 1 Siegel, R, Ma, J, Zou, Z, Jemal, A, Cancer statistics, 2014. CA Cancer J Clin 64:1 (2014), 9–29.
2. 2 Yabroff, KR, Lund, J, Kepka, D, Mariotto, A, Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev 20:10 (2011), 2006–2014.
3. 3 Aberle, DR, Adams, AM, Berg, CD, et al. National Lung Screening Trial Research Team Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:5 (2011), 395–409.
4. 4 MEDCAC meeting 4/30/2014 - lung cancer screening with low dose computed tomography. Centers for Medicare & Medicaid website. http://www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?MEDCACId=68#questions Accessed June 17.
5. 5 Bach, PB, Mirkin, JN, Oliver, TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 307:22 (2012), 2418–2429.
6. 6 Bach, PB, Cramer, LD, Schrag, D, Downey, RJ, Gelfand, SE, Begg, CB, The influence of hospital volume on survival after resection for lung cancer. N Engl J Med 345:3 (2001), 181–188.
7. 7 Boffa, DJ, Allen, MS, Grab, JD, Gaissert, HA, Harpole, DH, Wright, CD, Data from The Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors. J Thorac Cardiovasc Surg 135:2 (2008), 247–254.
8. 8 Sox, HC, Better evidence about screening for lung cancer. N Engl J Med 365:5 (2011), 455–457.
9. 9 Pinsky, PF, Miller, A, Kramer, BS, et al. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial. Am J Epidemiol 165:8 (2007), 874–881.
10. 10 Tammemägi, MC, Katki, HA, Hocking, WG, et al. Selection criteria for lung-cancer screening. N Engl J Med 368:8 (2013), 728–736.
11. 11 Pinsky, PF, Church, TR, Izmirlian, G, Kramer, BS, The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 119:22 (2013), 3976–3983.
12. 12 Roth, JA, Sullivan, SD, Ravelo, A, Sanderson, J, Ramsey, SD, Low-dose computed tomography lung cancer screening in the Medicare program: Projected clinical, resource, and budget impact [abstract 6501]. J Clin Oncol, 32, 2014, 5s.
13. 13 Connor Gorber, S, Schofield-Hurwitz, S, Hardt, J, Levasseur, G, Tremblay, M, The accuracy of self-reported smoking: a systematic review of the relationship between self-reported and cotinine-assessed smoking status. Nicotine Tob Res 11:1 (2009), 12–24.
14. 14 Marcus, PM, Bergstralh, EJ, Zweig, MH, Harris, A, Offord, KP, Fontana, RS, Extended lung cancer incidence follow-up in the Mayo Lung Project and overdiagnosis. J Natl Cancer Inst 98:11 (2006), 748–756.
15. 15 de Koning, HJ, Meza, R, Plevritis, SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the US Preventive Services Task Force. Ann Intern Med 160:5 (2014), 311–320.
16. 16 Little, AG, Gay, EG, Gaspar, LE, Stewart, AK, National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 57:3 (2007), 253–260.
17. 17 Draisma, G, Etzioni, R, Tsodikov, A, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101:6 (2009), 374–383.
18. 18 Brenner, DJ, Radiation risks potentially associated with low-dose CT screening of adult smokers for lung cancer. Radiology 231:2 (2004), 440–445.
19. 19 Harris, R, Screening is only part of the answer to breast cancer. Ann Intern Med 160:12 (2014), 861–863.
20. 20 Goulart, BH, Bensink, ME, Mummy, DG, Ramsey, SD, Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw 10:2 (2012), 267–275.
21. 21 Tunis, SR, Stryer, DB, Clancy, CM, Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 290:12 (2003), 1624–1632.
22. 22 Mdege, ND, Man, M-S, Taylor Nee Brown, CA, Torgerson, DJ, Systematic review of stepped wedge cluster randomized trials shows that design is particularly used to evaluate interventions during routine implementation. J Clin Epidemiol 64:9 (2011), 936–948.